---
title: "Retatrutide"
canonical_url: https://peptidelibrary.app/library/retatrutide
description: "Lilly triple agonist (GIP, GLP-1, glucagon receptors). Phase 3 trials have published in obesity (TRIUMPH-1, NEJM 2026) and type 2 diabetes (TRIUMPH-2 and TRANSCEND-T2D-1, Lancet 2026), and a head-to-head trial against semaglutide has reported topline results. Not FDA-approved; Lilly plans to submit it in Q1 2027."
updated: 2026-11-08
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Retatrutide

Retatrutide (also called LY3437943 or Triple GIP/GLP-1/glucagon agonist) is an investigational triple agonist in the GLP-1 Agonist class. Retatrutide is a single peptide agonist at three receptors — GIP, GLP-1 and glucagon — with an acyl chain supporting weekly dosing.

Lilly triple agonist (GIP, GLP-1, glucagon receptors). Phase 3 trials have published in obesity (TRIUMPH-1, NEJM 2026) and type 2 diabetes (TRIUMPH-2 and TRANSCEND-T2D-1, Lancet 2026), and a head-to-head trial against semaglutide has reported topline results. Not FDA-approved; Lilly plans to submit it in Q1 2027.

Also known as: LY3437943, Triple GIP/GLP-1/glucagon agonist.

Categories: Fat Loss, GLP-1/Metabolic.

## Classification

- Type: Investigational triple agonist
- Mechanism class: GLP-1 Agonist
- Development stage: In clinical development
- Regulatory class: Investigational, not FDA-approved

## Mechanism

Retatrutide is a single peptide agonist at three receptors — GIP, GLP-1 and glucagon — with an acyl chain supporting weekly dosing. Each arm contributes something different. GLP-1 receptor activation drives glucose-dependent insulin secretion and central appetite suppression; GIP receptor activation adds effects on adipose metabolism and hindbrain signalling; glucagon receptor activation raises hepatic energy expenditure and promotes fat oxidation, a catabolic effect that opposes the weight-sparing tendency of incretin action alone. Balancing glucagon agonism against its hyperglycaemic potential is the central design problem of the class, resolved here by pairing it with sufficient incretin activity.

Targets: GIP receptor, GLP-1 receptor, Glucagon receptor.

Origin: Synthetic fatty-acylated triple agonist (Lilly).

## Properties

- Sequence: Not publicly disclosed (triple agonist)
- Molecular formula: C221H342N46O68
- Molecular weight: ~4731 g/mol
- CAS number: 2381089-83-2
- Half-life: ~6 days (weekly injection in trials)
- Studied routes: Subcutaneous

## Evidence

- Evidence level: Clinical Trial Evidence
- Highest documented: Controlled human trials
- Human trials: 6
- Controlled human trials: 5
- Preclinical sources: 0
- Latest source: 2026

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. 2023. Controlled human trial. Population: Adults with obesity, or overweight with a weight-related condition (n=338). Percentage change in body weight [Source](https://pubmed.ncbi.nlm.nih.gov/37366315/)
2. Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo- and active-controlled, parallel-group, phase 2 trial. Lancet. 2023. 2023. Controlled human trial. Population: Adults with type 2 diabetes (n=281). Change in glycated haemoglobin [Source](https://pubmed.ncbi.nlm.nih.gov/37385280/)
3. Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024. 2024. Human study (early or uncontrolled). Population: Adults with obesity and metabolic dysfunction-associated steatotic liver disease. Liver fat content [Source](https://pubmed.ncbi.nlm.nih.gov/38858523/)
4. Bajaj HS et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026. 2026. Controlled human trial. Population: Adults with type 2 diabetes inadequately controlled by diet and exercise (n=537). Change in glycated haemoglobin; body weight a key secondary endpoint [Source](https://pubmed.ncbi.nlm.nih.gov/42250575/)
5. Jastreboff AM et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). N Engl J Med. 2026. 2026. Controlled human trial. Population: Adults with obesity or overweight without type 2 diabetes (n=2339). Percentage change in body weight at week 80 [Source](https://pubmed.ncbi.nlm.nih.gov/42814954/)
6. NCT06260722 — Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2). 2026. Controlled human trial. Population: Adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor (n=1298). Change in HbA1c versus semaglutide at week 80 [Source](https://clinicaltrials.gov/study/NCT06260722)

### Registered trials

- [NCT06260722](https://clinicaltrials.gov/study/NCT06260722)

## Safety

Side effects: Nausea; Diarrhea; Constipation; Increased heart rate.

Risks: Not approved — research vials are not a licensed drug; WADA S0.

Contraindications: Thyroid cancer history.

Human safety basis: Clinical trial reports

Key limitations: Not approved by the FDA for any use..

## Regulatory status

Retatrutide has been studied under an Investigational New Drug application. It is not approved for marketing.

- FDA status: Investigational New Drug (IND)
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What are the side effects of Retatrutide?

Side effects recorded for Retatrutide from clinical-trial reports include nausea, diarrhea, constipation and increased heart rate. Cautions recorded on this profile: thyroid cancer history. It is on the WADA Prohibited List for athletes. This is reference information, not medical advice.

### Is Retatrutide FDA approved?

No. Retatrutide is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.

### What is the half-life of Retatrutide?

Reported half-life for Retatrutide is ~6 days (weekly injection in trials). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of Retatrutide?

Retatrutide has the sequence Not publicly disclosed (triple agonist). Its molecular formula is C221H342N46O68.

### Is Retatrutide banned in sport?

Retatrutide is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

## References

- [Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA — Obesity (Silver Spring), 2025](https://pubmed.ncbi.nlm.nih.gov/40685589/)
- [Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial — Lancet, 2026](https://pubmed.ncbi.nlm.nih.gov/42250575/)
- [Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial — Lancet Diabetes Endocrinol, 2025](https://pubmed.ncbi.nlm.nih.gov/40609566/)
- [Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial — Nat Med, 2024](https://pubmed.ncbi.nlm.nih.gov/38858523/)
- [Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA — Lancet, 2023](https://pubmed.ncbi.nlm.nih.gov/37385280/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
